Last update 22 Mar 2025

UBP Greater China Holdings Limited

Private Company|
2016|
Hong Kong, China

Overview

Tags

Skin and Musculoskeletal Diseases
Immune System Diseases
Infectious Diseases
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Immune System Diseases2
Infectious Diseases2
Top 5 Drug TypeCount
Monoclonal antibody3
Top 5 TargetCount
IgE(Immunoglobulin E)1
CD4(T-cell surface antigen CD4)1
HSV gD1

Related

3
Drugs associated with UBP Greater China Holdings Limited
Semzuvolimab
Target
CD4
Mechanism
CD4 inhibitors [+1]
Active Org.
UBP Greater China Holdings Limited [+2]
Originator Org.
United Biomedical, Inc.United Biomedical, Inc.
Active Indication
HIV Infections
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
UB-621
Target
HSV gD
Mechanism
HSV gD inhibitors
Active Org.
UBP Greater China Holdings Limited
Originator Org.
United BioPharma, Inc.United BioPharma, Inc.
Active Indication
Herpes Genitalis
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
UB-221
Target
IgE
Mechanism
IgE inhibitors
Active Org.
Liansheng Pharmaceutical (Yangzhou) Biomedical Co., Ltd. [+1]
Originator Org.
Academia SinicaAcademia Sinica
Active Indication
Chronic Urticaria
Inactive Indication
Allergic asthma [+3]
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
5
Clinical Trials associated with UBP Greater China Holdings Limited
NCT04985890
/ Not yet recruitingPhase 2
A Proof of Concept Study to Evaluate the Safety and Efficacy of UB-421 in Combination With Chidamide for Reduction of HIV Reservoir as Compared to UB-421 Alone in ART Stabilized HIV-1 Patients Who Undergo ART Interruption
NCT04404023
/ Not yet recruitingPhase 1
A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of a Single Dose of UB-221 in Healthy Volunteers
NCT04979975
/ Not yet recruitingPhase 2
A Randomized, Single-blind, Placebo-control, Parallel, Phase II Trial to Evaluate the Safety and Efficacy of UB-621 in Adults With Recurrent Genital HSV-2 Infection
100 Clinical Results associated with UBP Greater China Holdings Limited
Login to view more data
0 Patents (Medical) associated with UBP Greater China Holdings Limited
Login to view more data
100 Deals associated with UBP Greater China Holdings Limited
Login to view more data
100 Translational Medicine associated with UBP Greater China Holdings Limited
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 29 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1
1
2
Phase 2
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
UB-621
 ( HSV gD )		Herpes Genitalis
More
Phase 2
Semzuvolimab
 ( CD4 )		HIV Infections
More
Phase 2
UB-221
 ( IgE )		Chronic Urticaria
More
Phase 1
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free